Table III. —Participants characteristics (N.=48).
| Variables | PR-BT (N.=24) |
PR (N.=24) |
P value* |
|---|---|---|---|
| Age (years) | 74.5±5.3 | 75.4±6.8 | 0.62 |
| Gender (male, %) | 20 (83) | 12 (50) | 0.01 |
| BMI (kg/m2) | 19.4±3.5 | 17.9±4.0 | 0.17 |
| FEV1 (L) | 0.8±0.4 | 0.7±0.4 | 0.42 |
| FVC (L) | 1.6±0.6 | 1.3±0.6 | 0.16 |
| FEV1/FVC (%) | 51.4±10.9 | 55.1±9.8 | 0.22 |
| Predicted FEV1 (%) | 62.9±17.4 | 53.3±17.7 | 0.06 |
| Stage of airflow obstruction (Mdn, IQR) | 2 (0.75) | 2 (1) | 0.23 |
| GOLD stage I (%) | 3 (13) | 3 (13) | - |
| GOLD stage II (%) | 15 (62) | 10 (42) | - |
| GOLD stage III (%) | 5 (21) | 9 (37) | - |
| GOLD stage IV (%) | 1 (4) | 2 (8) | - |
| mMRC dyspnea (Mdn, IQR) | 2 (2) | 2 (2) | 0.56 |
| Level 0 (N., %) | 3 (13) | 4 (17) | - |
| Level 1 (N., %) | 8 (33) | 3 (13) | - |
| Level 2 (N., %) | 5 (21) | 8 (33) | - |
| Level 3 (N., %) | 8 (33) | 9 (37) | - |
| Level 4 (N., %) | 0 (0) | 0 (0) | - |
| Current smoker (N., %) | 13 (54.17) | 13 (54.17) | 1.00 |
| Medication used (N., %) | 24 (100.0) | 24 (100.0) | 0.9 |
| 1 type (N.) | 11 | 13 | - |
| 2 types (N.) | 6 | 6 | - |
| 3 types (N.) | 6 | 4 | - |
| ≥4 types (N.) | 1 | 1 | - |
| Co-morbidity (N., %) | 13 (54) | 11 (46) | 0.9 |
| 1 disease (N.) | 6 | 6 | - |
| 2 diseases (N.) | 6 | 4 | - |
| 3 diseases (N.) | 1 | 1 | - |
The data are expressed as mean±standard deviation, otherwise as indicated. *Using Independent sample t-test, except for gender, current smoker, co-morbidity and medication (using χ2 Test) and mMRC dyspnea, and disease severity (using Mann-Whitney U test). BMI: Body Mass Index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; PR: pulmonary rehabilitation group; PR-BT: balance training combined with PR group; IQR: interquartile range; kg: kilogram; m2: square meter; Mdn: median; N.: number.